Clinical Trials Browser

Completed × Interventional × darolutamide × Clear all

NCT04925648 2026-04-23

PICASSO

Phase 2 Completed

Prostatic Neoplasms

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05171387 2025-06-22

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT03314324 2025-04-17

ODENZA

Phase 2 Completed

Neoplasms

NCT03383679 2022-11-21

START

Phase 2 Completed

Breast Cancer Female

NCT02200614 2022-06-28

ARAMIS

Phase 3 Completed

1,509 enrolled 13 charts 1 FDA

Prostate Cancer Non-Metastatic

NCT01784757 2021-03-17

ARAFOR

Phase 1 Completed

Prostatic Neoplasms

NCT03004534 2020-04-03

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Phase EARLY_PHASE1 Completed

36 enrolled 10 charts

Breast Neoplasms

NCT03237416 2018-11-06

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Phase 1 Completed

Prostatic Neoplasms

NCT01317641 2017-03-29

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Phase 1/2 Completed

136 enrolled 28 charts

Prostatic Neoplasms

NCT01429064 2017-02-20

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Phase 2 Completed

76 enrolled 9 charts

Prostatic Neoplasms

NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Phase 1 Completed

Healthy Volunteers